BioSpace News Archive

Novo Seeds, the early stage investment arm of Novo Holdings, wholly owned by the Novo Nordisk Foundation, today publishes its review of 2018 - a record year with six new investments, two portfolio companies closed major financing rounds, the launch of the REPAIR Impact Fund and significant expansion of the team

Ascension Healthcare plc (“Ascension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for haemophilia and osteoarthritis today provides a business update and announces a Company change of name from Pro Bono Bio.

AmpliPhi Biosciences Corporation and C3J Therapeutics, Inc. (“C3J”), a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials, today announced that the companies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge with C3J

Technavio analysts forecast the global transcranial doppler market to grow at a CAGR of close to 7% during the forecast period, according to their latest market research report.

Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that, under the terms of a reorganization and share exchange agreement approved by the Board of Directors, it has acquired from Bay City Capital (BCC) the remaining 20% equity share of its device subsidiary, ThermoGenesis Corp.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Jennifer Jarrett will step down as the Company’s Chief Financial and Operating Officer, effective January 11, 2019, to pursue an opportunity at a privately-held transportation and technology company.

Jenny Craig is featured in PEOPLE’s “Half Their Size” issue, on newsstands nationwide

Global Genomics Group announced that a patent for its first precision diagnostic biomarker for the detection of plaque buildup in the heart has been granted by the United States Patent and Trademark office

FDA says proposed Phase 2 clinical trial may proceed

PierianDx, a leading clinical genomics informatics company, today announced a strategic, non-exclusive, multi-year partnership with Illumina, Inc. to provide a variant interpretation and reporting solution based on PierianDx’s Clinical Genomics Workspace platform and Clinical Genomics Knowledgebase for select Illumina oncology products.